Triplet Not Always Better Than Doublet in mCSPC
First-line systemic therapy in patients with metastatic castration-sensitive prostate cancer should be based on individual disease and patient characteristics, results of a meta-analysis suggest.
Medscape Medical News
source https://www.medscape.com/viewarticle/989059?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/989059?src=rss
Comments
Post a Comment